Eko Closes $5M Series A

On the Heels of Adoption with Clinicians at 1,000+ Hospitals and Health Systems, Next Generation Digital Health Company to Commence Clinical Studies and Integrate Heart Disease Screening Algorithms Into Platform

Bringing Intelligence to Heart Sounds, Eko Closes $5 Million Series A Led by ARTIS Ventures

San Francisco
January 28, 2018

Eko, the leader in acoustic cardiac monitoring, today announced a $5 million Series A led by ARTIS Ventures. Additional investors in the round include Dreamlt Ventures, 1812 Ventures, and FOUNDER.org. The funding will be used to grow Eko’s commercial team and to expand clinical studies on the use of Eko’s platform for valvular heart disease screening and heart failure monitoring.

According to the American Heart Association, more than 92 million adults are living with some form of cardiovascular disease or the after-effects of stroke, and direct and indirect costs of these ailments are estimated to total more than $316 billion. Eko’s FDA-cleared devices and accompanying software, which are used by clinicians at more than 1,000 hospitals and health systems, help physicians better monitor their patient’s cardiac health, both in the hospital and at the patient’s home.

“We partner with investors that are passionate about solving meaningful problems; together we can transform the way clinicians and patients monitor heart disease,” said Connor Landgraf, Eko’s co-founder and CEO. “This investment will enable us to integrate cardiac decision algorithms into our platform to help physicians better track their patients’ cardiac health.”

In addition to its recent FDA clearance of Eko DUO, Eko has received UCSF’s Institutional Review Board (IRB) approval for a clinical study focused on valvular heart disease screenings. The study will be led by Dr. John Chorba, Associate Professor and Cardiologist at UCSF.

“Eko and ARTIS Ventures are of likemind in that we both want to tackle the use of technology to improve people’s lives, and for the longest time we’ve relied on the ability for a trained ear to diagnose heart problems,” said Vasudev Bailey, partner at ARTIS Ventures. “By elegantly applying machine learning to the largest database of sounds, Eko has made it possible for physicians and consumers to imagine a world where we can quickly and easily diagnose medical conditions. While cardiology is a natural starting place, the solutions have extensions to pulmonology and gastroenterology as well, without forcing a change in patient–physician flow. Their solution easily provides a smarter way to track, and diagnose, medical aberrations.”

For more information about Eko and its products visit https://ekohealth.com/.

Eko, a digital health company, is advancing how healthcare professionals detect and monitor heart and lung disease with its innovative suite of digital tools, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko is headquartered in Oakland, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others.

Eko Devices, Inc.
1212 Broadway, Suite 100
Oakland, CA 94612

Highwire PR
Sign up for a Demo
A member of our team will respond with one business day.